Odyssey Therapeutics debuted on Nasdaq with an 11.1% surge, reaching a $899.9 million valuation. The autoimmune disease specialist successfully raised $279 million in its IPO, exceeding its target. This strong performance signals a revitalized biotech IPO market, with investors showing renewed confidence. Founder Dr. Gary D. Glick's prior success further bolsters investor appeal.